en · de · es · fr · pt
semax-notes.peptides4800.com › Data › Semax Origin And Molecular Structure — Deep Dive

Semax Origin And Molecular Structure — Deep Dive

By Editorial Desk · published 2026-06-12 · last reviewed 2026-06-29 · Data

Certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-06-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Semax Origin and Molecular Structure

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Mechanisms and Research Directions

Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.

Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.

Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SFree acid form of the heptapeptide; depends on terminal groups
Molecular massAbout 813.9 g/molAverage mass used for mass spectrometry confirmation
AppearanceWhite to off-white solidSupplied as a lyophilised powder; hygroscopic
Solubility classFreely soluble in aqueous mediaWater, saline, and phosphate buffers; limited organic solubility
Typical storage temperature-20 degrees CelsiusLong term and dry; short working periods may use 2 to 8 degrees Celsius

Semax Peptide Structure and Origin

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Related pages on this site

Analytical Testing And Storage

Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.

The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.

Reference notes

However, if someone with the phenylketonuria mutation follows a strict diet that avoids this amino acid, they remain normal and healthy. A common method for determining how genes and environment ("nature and nurture") contribute to a phenotype involves studying identical and fraternal twins, or other siblings of multiple births. Identical siblings are genetically the same since they come from the same zygote. Meanwhile, fraternal twins are as genetically different from one another as normal siblings. By comparing how often a certain disorder occurs in a pair of identical twins to how often it occurs in a pair of fraternal twins, scientists can determine whether that disorder is caused by genetic or postnatal environmental factors. One famous example involved the study of the Genain quadruplets, who were identical quadruplets all diagnosed with schizophrenia.

The British implemented a scorched earth policy under which they targeted everything within the controlled areas that could give sustenance to the guerrillas, making it harder for them to survive. As British troops swept the countryside, they systematically destroyed crops, poisoned wells, burned homesteads and farms, and interned Boer and African men, women, children and workers in concentration camps. The British established mounted raiding columns in support of sweeper columns. These were used to rapidly follow and relentlessly harass the Boers to delay them and cut off escape, while the sweeper units caught up. Many of the 90 or so mobile columns formed by the British to participate in such drives were a mixture of British and colonial troops, but they also had a large minority of armed Africans. The number of armed Africans serving with these columns has been estimated at 20,000. The British Army made use of Boer auxiliaries who had been persuaded to change sides and enlist as "National Scouts". Serving under General Andries Cronjé (1849–1923), the National Scouts were despised as joiners but numbered a fifth of the fighting Afrikaners by the end of the War. The British utilised armoured trains to deliver rapid reaction forces much more quickly to incidents (such as Boer attacks on blockhouses and columns) or drop them off ahead of retreating Boer columns.

Failure to thrive due to feeding difficulties Axial muscle weakness, particularly affecting neck and trunk flexors High pitched voice Myopathic facial features A high arched or cleft palate may be present. Later developing features include a progressive scoliosis and respiratory impairment. Ophthalmoplegic form (5–10% cases) This typically presents with weakness of abduction and upward gaze. Ptosis may occur. There is also weakness of the proximal limb muscles. Progressive form with hand involvement (10% cases) The type presents with progressive hand weakness and hypermobility. Hip girdle weakness may be present and exercise induced myalgia is common. Scoliosis and respiratory problems are mild or absent. Antenatal form with arthrogryposis multiplex congenita (10% cases) This diagnosis may be suspected prenatally with reduced fetal movements and polyhydramnios. This typically presents with contractures at birth due to poor foetal movement. Other features include a long head, low set ears and a short neck. The respiratory muscles can be moderately to severely affected and problems with breathing are common.

Sources: en.wikipedia.org

Reference notes

Weak affinity chromatography (WAC) is an affinity chromatography technique for affinity screening in drug development. WAC is an affinity-based liquid chromatographic technique that separates chemical compounds based on their different weak affinities to an immobilized target. The higher affinity a compound has towards the target, the longer it remains in the separation unit, and this will be expressed as a longer retention time. The affinity measure and ranking of affinity can be achieved by processing the obtained retention times of analyzed compounds. Affinity chromatography is part of a larger suite of techniques used in chemoproteomics based drug target identification. The WAC technology is demonstrated against a number of different protein targets – proteases, kinases, chaperones and protein–protein interaction (PPI) targets. WAC has been shown to be more effective than established methods for fragment based screening. Affinity chromatography was conceived and first developed by Pedro Cuatrecasas and Meir Wilchek.

Business biomimetics is the latest development in the application of biomimetics. Specifically it applies principles and practice from biological systems to business strategy, process, organization design, and strategic thinking. It has been successfully used by a range of industries in FMCG, defense, central government, packaging, and business services. Based on the work by Phil Richardson at the University of Bath the approach was launched at the House of Lords in May 2009. Generally, biometrics is used as a creativity technique that studies biological prototypes to get ideas for engineering solutions. In chemistry, a biomimetic synthesis is a chemical synthesis inspired by biochemical processes. Another, more recent meaning of the term bionics refers to merging organism and machine. This approach results in a hybrid system combining biological and engineering parts, which can also be referred as a cybernetic organism (cyborg). Practical realization of this was demonstrated in Kevin Warwick's implant experiments bringing about ultrasound input via his own nervous system.

The most commonly used dye in agarose gel gel electrophoresis of DNA and RNA, dating as far back as the 1970s, is ethidium bromide (2,7-diamino-10-ethyl-9-phenylphenanthridiniumbromide). Ethidium Bromide (EtBr) is an orange-colored fluorescent intercalating dye. The dye inserts itself between the double helical structure of nucleic acids, allowing for visualization of the molecules under UV light. EtBr has absorbance maxima at 300-360 nm and fluorescent emission maxima at 500-590 nm, with the detection limit of 0.5-5.0 ng/band. The dye, however, has reduced sensitivity in the detection of single-stranded nucleic acid samples. EtBr should be handled with care, as it is a potent mutagen. A more sensitive alternative for nucleic acid staining in gel electrophoresis is SYBR™ Green I. The dye is 25 times more sensitive than EtBr in the staining of dsDNA, and is especially useful in staining assays containing single-stranded nucleic acids. SYBR Green is, however, more expensive when compared to EtBr.

Sources: en.wikipedia.org

Frequently asked questions

What is semax derived from?

It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.

Is semax an approved medicine outside Russia?

It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.

What is known about its mechanism?

Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.

What is the leading proposed mechanism?

The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.

Network